Moderna, Inc. (ETR:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 18.82B +107.4% |
| Revenue (ttm) | 1.66B -39.9% |
| Net Income | -2.40B |
| EPS | -6.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,621 |
| Average Volume | 7,441 |
| Open | 47.39 |
| Previous Close | 46.90 |
| Day's Range | 46.43 - 48.00 |
| 52-Week Range | 19.37 - 50.57 |
| Beta | 1.34 |
| RSI | 59.39 |
| Earnings Date | May 1, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna starts late-stage trial of bird flu vaccine in US, UK
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, marking the first time a pandemic bird flu vaccine made with mRNA technology ha...
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 2...
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on it...
Moderna wins EU approval for combined flu, COVID shot for older adults
Moderna said on Tuesday the European Commission had granted marketing authorization for a combination vaccine for the prevention of influenza and COVID-19 in adults 50 years of age and ...
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, sub...
Moderna to Present at Upcoming Conferences in May 2026
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Confer...
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TP...
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its ...
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, i...
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his position...
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and a...
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Moderna Inc. (NASDAQ: MRNA) shares are up during Wednesday's premarket session following a settlement agreement with Arbutus Biopharma Corporation (NASDAQ: ABUS) and Roivant Inc.'s (NASDAQ: ROIV) Gene...
Moderna Stock Rallies. This Big Risk Just Got Eliminated.
The company settles to resove patent litigation related to its Covid-19 vaccine, removing an overhang for shares.
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir...
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive ...
Moderna gets EU regulator nod for combined COVID, flu vaccine
Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for people aged 50 and older ag...
Moderna Stock: How Far Can The Flu Shot Fly?
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increa...
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccin...